CereVasc, Inc. Announces Results of Groundbreaking Clinical Study of the eShunt® System in the Treatment of Elderly Patients with Normal Pressure Hydrocephalus

97% of subjects treated (29/30) experienced improvement in clinical symptoms of NPH 0 Serious Adverse Events (SAEs) related to the study device or procedure BOSTON, Feb. 5, 2025 /PRNewswire/ -- CereVasc, Inc., a clinical-stage medical device company developing novel treatments for...